A recombinant vaccinia virus expressing herpes simplex virus type 1 (HSV-1) glycoprotein G (gG) has been constructed. Cells infected with this recombinant virus (gG-VAC) synthesized glycosylated proteins of 48K, 57K and 61K tool. wt. that were recognized by anti-HSV-1 sera. Rabbits and mice vaccinated with the live recombinant virus produced antibodies that recognized 48K, 57K and 61K mol. wt. proteins in HSV-l-infected cells. The gG polypeptides were present on cytoplasmic and nuclear membranes during infection with both HSV-1 and recombinant vaccinia virus gG-VAC. The 57K and 61K tool. wt. gG polypeptides were present in purified HSV-1 virions and were targets for antibody-mediated complement-dependent virus neutralization.
INTRODUCTION
Herpes simplex viruses (HSV) encode several glycoproteins which are incorporated into the virion envelope and membranes of infected cells. The glycoproteins are involved in adsorption, entry and cell-to-cell spread of the virus during infection, and can be targets for both humoral and cellular immune responses. Four HSV glycoproteins (gB, gC, gD and gE) have been identified for some time and their genomic map positions and nucleotide sequences determined (Bzik et al., 1984; Pellet et al., 1985; Frink et al., 1983; Watson et al., 1982; McGeoch et al., 1985) . However, relatively little is known about their specific biological functions (for review, see Spear, 1984) . Glycoprotein B has been implicated in viral penetration (Little et al., 1981 ; Sarmiento et al., 1979) : gC is a receptor for the C3b component of complement (Friedman et al., 1984) : gE is a receptor for the Fc portion of immunoglobulins (Bauke & Spear, 1979 ; Para et al., 1982a, b) ; gD is a major target for virus-neutralizing antibodies (Para et al., 1985) and has also been implicated in cell fusion (Noble et al., 1983) . More recently another HSV type 1 (HSV-1) glycoprotein designated gH has been identified and mapped on the genome using monoclonal antibodies (Showalter et al., 1981; Buckmaster et al., 1984) and its nucleotide sequence determined (McGeoch & Davison, 1986; Gompels & Minson, 1986) . Monoclonal antibodies against gH neutralize HSV-1 infectivity, and inhibit infected cell fusion and plaque formation (Gompels & Minson, 1986) . In addition Roizman et al. (1984) identified a 120K glycoprotein in HSV-2-infected cells designated gG, since shown to be the same as the 92K glycoprotein identified by Marsden et al. (1984) .
The nucleotide sequence of the unique short component of HSV-1 DNA (McGeoch et al., 1985) revealed three previously unidentified open reading frames whose predicted primary translation products showed the characteristic features of membrane glycoproteins. The products of one of these, US4, are the targets of monoclonal antibodies LP10 (Richman et al., 1986) and H 1379 (Ackerman et al., 1986) . Antisera against a synthetic peptide corresponding to a small region of the predicted US4 polypeptide recognize several glycoprotein species in HSV-l-infected cells and virions (Frame et al., 1986) . The US4 gene is now considered to code for the HSV-1 counterpart of gG-2 which maps at a similar position to the left of gD on the 0000-7833 © 1987 SGM HSV-2 genome. This has been confirmed by comparison of the nucleotide sequence of US4 with that of gG-2 (McGeoch et al., 1987) .
To investigate further the polypeptides specified by this gene we have constructed a vaccinia virus recombinant that expresses the HSV-1 gG gene. Several HSV-l-specific polypeptides are synthesized in cells infected with this recombinant. Animals vaccinated with the recombinant virus produced antibodies that recognized the same sized polypeptides in HSV-l-infected cells and which neutralized HSV-1 infectivity in vitro.
METHODS
Cells. BHK-21 clone 13 cells were maintained in Glasgow-modified Eagle's medium (GMEM) containing 10~ tryptose phosphate broth and 10 ~ newborn calf serum. African green monkey (CV-1) cells and human thymidine kinase-negative (TK-) 143 cells were maintained in GMEM containing 10~ foetal bovine serum and, in the case of TK-cells, 25 ~tg/ml 5-bromodeoxyuridine was included. HeLa $3 cells were grown in suspension culture medium (Gibco) containing 5~ horse serum.
Viruses. HSV-1 strains SC16 and HFEM were grown and titrated in BHK cells and purified on potassium tartrate gradients as described (Richman et al., 1986) . Vaccinia virus strain WR and the recombinant vaccinia virus gG-VAC were grown in HeLa cells and titrated on CV-I cells (Macken et aL, 1985) .
Plasmid eonstruction. The HSV-1 (SC 16) gG gene was obtained from plasmid pSP64 containing the gG-coding region (Richman et al., 1986) by digestion with Hincll and EcoRI and isolation of a 1.03 kb fragment. This HincIIEcoRI fragment was cloned into plasmid pGS62 (Mackett et al., 1984 : Smith et al., 1987 that had been cut with Sinai and EcoRI and dephosphorylated. The orientation of the gG gene with respect to the vaccinia virus promoter was confirmed by restriction enzyme analysis and the resultant plasmid termed pGG1.
Construction of vaccinia virus recombinant. Plasmid pGG1 was used to construct a TK-vaccinia virus recombinant containing the HSV-1 gG-coding region (gG-VAC) using established transfection, selection and purification methods (Mackett et al., 1984 (Mackett et al., , 1985 .
Immunoprecipitation. CV-1 cells infected at 30 p.f.u./cell with either wild-type vaccinia virus (WT-VAC) or gG-VAC, or mock-infected, were incubated in methionine-free medium from 3 to 3.5 h post-infection and then radiolabelled by incubation in 100 ixCi/ml of [3sS]methionine in MEM without methionine for 2.5 h. BHK cells infected at l0 p.f.u./cell with HSV-1 or mock-infected were incubated in methionine-free medium from 5.5 to 6 h post-infection and radiolabelled with [3sS]methionine for 1 h. The cells were lysed in RIPA buffer (50 mM-Tris-HCI pH 7.2, 150 mM-NaCI, 1 ~ sodium deoxycholate, 0.1 ~ SDS, 1 ~ Triton X-100) plus 5 ~tg/ml DNase and 2 mMphenylmethylsulphonyl fluoride for 15 min on ice and lysates were clarified by centrifugation at 31000 r.p.m, for 1 h at 4 °C in a Beckman SW50 rotor. Supernatants were incubated with rabbit serum or monoclonal antibodies for 20 min at room temperature and immune complexes were precipitated by incubation with 50 ~tl of a 50~ suspension of Protein A-Sepharose for 2 h at 4 °C. The beads were washed three times with RIPA buffer then boiled for 3 min with Laemmli sample buffer (24 mM-Tris-HC1 pH 6-8, 100 mM-dithiothreitol, 2% SDS, 20% glycerol, 0.02~ bromophenol blue) and separated by electrophoresis on 10~ polyacrylamide gels. The gels were then fixed, dried and autoradiographs were prepared.
Western blot analysis. BHK cells infected at 10 p.f.u./cell with HSV-I strains SC16 or HFEM, or mock-infected, were harvested at 8 h post-infection. BHK cells infected with WT-VAC, gG-VAC or mock-infected were harvested at 16 h post-infection. Tunicamycin was added at 10 ~tg/ml 30 min before infection and maintained during infection where indicated. Equal volumes of cell lysates and 2 x Laemmli buffer were mixed, boiled for 3 min and separated by electrophoresis on 10~ polyacrylamide gels. Proteins within the gel were blotted onto nitrocellulose filters by electrophoresis in transfer buffer (25 mM-Tris, 0.2 M-glycine pH 8.3, 20~ methanol) at 250 mA for 16 h. The nitrocellulose filters were incubated in 3 ~ bovine serum albumin (BSA) in phosphate-buffered saline (PBS) at 37 °C for 1 h then duplicate strips were incubated with rabbit sera or monoclonal antibodies diluted in 3 ~ BSA in PBS for 1 h at room temperature. After a 30 min wash in 1 ~ N P40 in PBS the filters were incubated with [~25I]Protein A-Sepharose (affinity purified), diluted to 0-2 ~Ci/mI in I~ BSA in PBS for 1 h at room temperature, then washed for 20 rain in 1 ~ NP40 in PBS, dried and autoradiographed.
RESULTS
Vaccinia virus recombinants are constructed in two steps. First, the foreign gene is cloned into a plasmid downstream of a vaccinia virus promoter and flanked by vaccinia virus DNA taken from a non-essential region of the virus genome. Second, the chimeric gene is inserted into the vaccinia virus genome by homologous recombination in cells infected with vaccinia virus and transfected with the recombinant plasmid (for review, see Mackett & Smith, 1986) . The gGcoding region of HSV-1 strain SC16 is present in a 1030 bp HincII-EcoRI DNA fragment that includes 38 bp upstream and 335 bp downstream from the gG gene (Richman et aL, 1986) . This fragment was cloned downstream from a vaccinia virus promoter (7.5K) in plasmid pGS62 (derived from pGS20, Mackett et al., 1984; Smith et al., 1987) . The resultant plasmid, pGGI, contained the ATG of the gG gene as the first translational initiation codon downstream from the vaccinia virus promoter RNA start sites. This plasmid was used to construct a TKrecombinant virus gG-VAC using standard techniques (Mackett et al., 1984) . To confirm the correct insertion of the gG gene within gG-VAC, DNA was extracted from purified virus and analysed by restriction endonuclease digestion, agarose gel electrophoresis and Southern blotting (Southern, 1975) . As predicted, the gG gene was correctly positioned downstream from the vaccinia virus promoter within the vaccinia virus TK gene (data not shown).
Expression and localization of gG in infected cells
Evidence for expression of gG in gG-VAC-infected cells was obtained by indirect immunofluorescence using a monoclonal antibody LP10 which recognizes the product of the US4 gene (Richman et al., 1986) followed by fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse IgG (Fig. I) . In non-permeabilized gG-VAC-infected cells LP10 binds to the cell surface (Fig. 1 a) whereas no binding was observed on WT-VAC-infected cells (Fig. 1 b) . If gG-VAC-infected cells were permeabilized prior to antibody binding, internal gG was detected in the cytoplasm and on the nuclear membrane (Fig. 1 c) . LP10 did not bind to WT-VACinfected cells (Fig. 1 d) .
An analysis of the location of gG in HSV-l-infected cells is shown in Fig. 1 (e to h). These experiments were complicated by the Fc-binding capacity of HSV-infected cells causing high backgrounds. To overcome this problem HSV-l-infected cells were first incubated with rabbit sera before LP10 and FITC-conjugated rabbit anti-mouse antibody ( Fig. le and g ). Glycoprotein G was present at the cell surface (Fig. 1 e) and within the cytoplasm and nuclear membrane (Fig. lg) in HSV-l-infected cells. As a further control a HSV-2-specific monoclonal antibody (AP5) was tested in parallel (Fig. lfand h) . Although some background was obtained with AP5 much greater binding was observed with LP10.
To characterize the gG polypeptides produced in cells infected with gG-VAC, [35S]methionine-labelled cell lysates were precipitated with monoclonal antibody LP10 (Fig. 2) . This antibody precipitated a 48K mol. wt. polypeptide from gG-VAC-infected cells which comigrated with a partially glycosylated gG polypeptide in HSV-l-infected cells (Richman et al., 1986) . This polypeptide was not detectable in either WT-VAC or mock-infected cells. In contrast, other polypeptides from gG-VAC-infected cells were also present in WT-VAC-but not mock-infected cells. These are, therefore, likely to be vaccinia virus proteins and not gG.
Vaccination of rabbits with gG-VA C Two rabbits were immunized by intradermal inoculation of purified infectious virus gG-VAC and revaccinated similarly 35 days later. Sera taken from these animals (anti-gG-VAC) or from a control rabbit immunized with a different TK-vaccinia virus recombinant expressing the L1 gene of human papillomavirus 16 (anti L1-VAC), or monoclonal antibody LP10 were used to precipitate [35S]methionine-labelled HSV-l-infected cell lysates (Fig. 3) . The 48K mol. wt. polypeptide recognized by LP10 was also precipitated by sera from both rabbits (3 and 4) immunized with gG-VAC, but not with sera from the control rabbit (anti L1-VAC). Higher tool. wt. polypeptides (53K and 73K) were efficiently precipitated from HSV-l-infected cells with all rabbit sera tested. Clearly these are not specific to gG and may be related to gE which, due to its Fc immunoglobulin-binding capacity, is reactive with immune sera (Bauke & Spear, 1979; Para et al., 1982a, b) .
Immunoblot analysis of HS V-1 polypeptides using anti-gG-VAC sera
In an attempt to reduce the high background caused by non-specific binding of rabbit sera to HSV-l-infected cell lysates, analyses were carried out using immunoblotting. Lysates of cells infected with HSV-I strains SC16 or HFEM were resolved on polyacrylamide gels and polypeptides transferred to nitrocellulose filters. These were then incubated with various antibodies and bound antibody was detected using 125i_labelled Protein A (Fig. 4) . By the use of this method the background was dramatically reduced so that with preimmune and anti-L1-VAC rabbit sera very little binding was observed. In contrast, anti-gG-VAC sera recognized three polypeptides from HSV-1 SC 16-infected cell lysates or two from HSV-1 HFEM-infected lysates. These were HSV-specific since the same sera did not react with uninfected cells. The polypeptides had mol. wt. of 48K, 57K and 61K. The 48K polypeptide comigrated with the major polypeptide recognized by LP10. This protein was present in HFEM-infected cells in reduced amounts, or reacted more weakly with antibodies, but was visible on longer exposure of the autoradiograph. The 57K and 61K mol. wt. forms were present in similar amounts in both strains and could also be detected with LP10 on long exposure. In some experiments the 57K mol. wt. band could be resolved into two closely migrating bands. A comparison of the gG polypeptides synthesized in gG-VAC-and HSV-l-infected cells in the presence and absence of tunicamycin is shown in Fig. 5 . In HSV-l-infected cells the gG polypeptides of mol. wt. 48K, 57K and 61K were replaced in the presence of tunicamycin by polypeptides of 39K, 50K and 55K mol. wt. The rabbit anti-gG-VAC sera did not recognize these proteins in uninfected cells. LPI0 also recognized the same three proteins in the presence of tunicamycin (data not shown). In gG-VAC-infected cells rabbit anti-HSV-1 sera recognized polypeptides of 48K, 57K and 61K tool. wt. In the presence of tunicamycin, proteins of 39K, 50K and 55K mol. wt. were seen instead. Control experiments showed that none of these smaller proteinssynthesized in the presence of tunicamycin was recognized by rabbit anti-L1-VAC sera (data not shown).
gG polypeptides in HSV-1 virions
Purified HSV-1 particles were tested for the presence of gG polypeptides by immunoblotting (Fig. 6 ). For comparison, HFEM-or SC 16-infected cell lysates were also included. Monoclonal antibody LPI0 recognized the 48K tool. wt. polypeptide in SC16-infected cell lysates ( lane 4) and, as noticed previously (Fig. 4) , this was not detected in HFEM-infected cells (Fig. 6 , lane 2). LP10 also recognized protein migrating in the 57K to 61K tool. wt. range in HSV-1 H F E M virions (Fig. 6, lane 3) . This was surprising since this monoclonal antibody did not efficiently recognize these bands in infected cells (Fig. 6, lane 2) . Anti-gG-VAC sera also detected the 48K, 57K and 61K tool. wt. species in HFEM-infected cells (Fig. 6 , lane 6) but in virions only the 57K and 61K tool. wt. species were present. A smaller band of 45K was probably non-specific since it was also present in both HFEM-infected and mock-infected cells on longer exposure. Both preimmune sera and anti-L 1-VAC sera failed to react with any HSV-1-infected cells or virions (Fig. 6, lanes 8 to 13) .
Neutralization o f HSV-1 infectivity with anti-gG-VAC
To determine whether the gG polypeptides present in purified HSV-1 virions are the target for neutralizing antibody, antisera from mice immunized with gG-VAC were tested for neutralization of HSV-1 infectivity in vitro (Fig. 7) . Pooled sera from groups of 10 mice immunized with recombinant gG-VAC or another TK-recombinant vaccinia virus expressing a Sehistosoma mansoni egg antigen fused to fl-galactosidase (YC3-VAC), were heated to inactivate endogenous complement and then reacted with HSV-1 in the presence of fresh or heat-inactivated exogenous complement. Residual infectivity was determined by plaque assay on BHK cell monolayers. Mouse anti-gG-VAC sera clearly neutralized HSV-1 infectivity in the presence of complement, whereas anti-YC3-VAC sera did not. Virus infectivity was neutralized by 87~o at low (1 : 10) dilutions of sera and 40~o neutralization was obtained at moderate (1:80) antibody dilution. No neutralization was obtained without the addition of fresh complement. Sera from rabbits immunized with gG-VAC were also able to neutralize HSV-1 infectivity by greater than 8 0~ in a complement-dependent manner (data not shown).
DISCUSSION
A recombinant vaccinia virus that expresses the HSV-1 gG (gG-VAC) has been constructed. In gG-VAC-infected cells gG-specific proteins of 48K, 57K and 61K mol. wt. were synthesized. Whereas all these proteins were efficiently recognized by polyvalent rabbit anti-HSV-1 sera, monoclonal antibody LP10 preferentially recognized the 48K mol. wt. form. Using rabbit antisera raised by vaccination with recombinant vaccinia gG-VAC, the same three polypeptides were detectable in HSV-l-infected cells. It was necessary to perform these experiments by immunoblotting since several other polypeptides were efficiently immunoprecipitated from HSV-l-infected cell lysates by anti-gG-VAC sera and by rabbit antibody to a vaccinia virus recombinant expressing an unrelated gene. Differences were observed in the relative Four weeks later the animals were reimmunized with the same viruses. Pooled sera taken 6 weeks after primary inoculation were heated at 56 °C for 1 h to inactivate complement and then diluted and mixed with HSV-1. After ificubation at 37 °C for 30 min, 2.5 ~ fresh (a) or heat-inactivated (b) rabbit complement was added. The mixture was then incubated at 37 °C for a further 30 min and residual infectivity assayed in duplicate on BHK cells. Plaques were counted 2 days later.
is consistent with the acquisition of HSV-1 envelopes by budding through this membrane. In addition, the migration of the gG to the nuclear membrane must be an intrinsic property of gG since it occurs in the absence of other HSV-1 proteins.
In HSV-1 virions both the 57K and 61K mol. wt. forms of gG were detectable. Frame et al. (1986) also detected smaller polypeptides of 37K and 48K mol. wt. Possibly the lack of the 48K form in our experiments reflects the HFEM strain used, since even in HFEM-infected cells this protein is a minor component.
The presence of gG polypeptides in virions suggested that anti-gG antibody may neutralize virus infectivity. Here we show that this is the case, but neutralization is dependent upon complement. This result differs from those obtained with both monoclonal antibodies LP10 and H1379 (Ackerman et al., 1986; Richman et al., 1986 ). Currently we are investigating whether polyvalent anti-gG-1 sera can neutralize HSV-2 infectivity. In this regard we have observed weak recognition of gG-VAC-infected cells by anti-HSV-2 sera. The homology between gG-1 and the carboxy-terminal region of gG-2 (McGeoch et al., 1987) and the observation that antisera raised against a peptide representing part of gG-1 are also cross-reactive with HSV-2 are also consistent with this result. Experiments are in progress to determine whether vaccination of mice with gG-VAC can prevent acute HSV-1 infection and establishment of latency. It will also be interesting to compare the degree of protection induced by gG-VAC with that induced by vaccinia virus recombinants expressing other HSV-1 glycoproteins (Paoletti et al., 1984; Cremer et al., 1985) .
